Core Viewpoint - Jilin Yatai Group's 2025 semi-annual report indicates a slight increase in revenue despite ongoing challenges in the construction and real estate sectors, with a focus on optimizing asset structure and reducing debt [1][2]. Company Overview and Financial Indicators - The company reported a revenue of approximately CNY 3.04 billion for the first half of 2025, representing a 3.67% increase compared to the same period last year [2]. - The total profit for the period was approximately -CNY 992 million, an improvement of 13.22% year-on-year [2]. - The net profit attributable to shareholders was approximately -CNY 823 million, showing an 11.27% improvement from the previous year [2]. - The company's net assets decreased by 32.58% to approximately CNY 1.87 billion compared to the end of the previous year [2]. Industry Analysis Construction Materials - The national cement production was 815 million tons, a year-on-year decrease of 4.3%, but the decline rate has narrowed [3]. - The cement industry is experiencing weak demand but improved profitability due to rising prices in Northeast China and decreasing coal prices [3]. Real Estate - Real estate development investment decreased by 11.2%, with new housing starts down by 20.0% and sales area down by 3.5% [3]. - The market is characterized by investment contraction and a narrowing decline in sales, with local policies aimed at stabilizing the market [3]. Pharmaceutical Industry - The pharmaceutical sector is expected to grow due to increasing demand for high-quality medicines driven by economic development and an aging population [3]. - The company has established a comprehensive health management service through its extensive pharmacy network [3]. Operational Discussion - The company is focusing on reducing debt and stabilizing operations while optimizing its asset structure [4]. - In the construction materials sector, the company is collaborating with large enterprises on urban renewal and infrastructure projects [4]. - The real estate sector is prioritizing inventory reduction and cost management, leveraging national policies to accelerate land monetization [4]. Financial Investment - The company holds a 30.81% stake in Northeast Securities and a 6.88% stake in Jilin Bank, focusing on equity management to enhance overall investment returns [7][9].

近日，有消费者向新京报记者反映，大连富生制药生产、销售的一款人参皂苷食品涉嫌抗肿瘤功效宣传。"原本想 买给家中患肿瘤的老人服用，但仔细一看竟是一款固体饮料，这不是妥妥的虚假宣传吗？"该消费者告诉记者，这 款在富生网健保健食品专营店售卖的人参皂苷产品，其主要成分为5年及5年以下人工种植的人参须，除此之外无 其他特殊成分。 新京报记者调查发现，这款售价高达1780元/盒的"富力博士人参皂苷Rg3"产品并非药品，真实身份仅为固体饮 料，属于普通食品。该产品还通过官网、电商页面的"科研成果展示""AI智能解答"等多种方式，暗示其具有抗肿 瘤功效，甚至与已获批的抗癌药物"参一胶囊"捆绑。 普通食品"嫁接"药品研发做宣传 在某网购平台的"富生网健保健食品专营店"，共有四款标注"人参皂苷Rg3"的产品，分别为Rg3人参浓缩液提取颗 粒固体饮料、人参复合固体饮料（木糖醇型）、Rg3人参金银花压片糖果、Rg3西洋参压片糖果，价格均为1780 元/盒。产品所标注的生产企业为大连富生制药有限公司，产品类别为"固体饮料""压片糖果"，均属普通食品。其 中，销量最高的Rg3人参浓缩液提取颗粒固体饮料配料表中，标注的成分为"5年及5年以 ...